Navigation Links
Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
Date:6/12/2008

Paris, France, Thursday, 12 June 2008: Adalimumab therapy is effective and well-tolerated in ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients with a previously inadequate response to anti-tumour necrosis factor (anti-TNF) therapies etanercept and infliximab, according to results of research presented today at EULAR 2008, the Annual European Congress of Rheumatology in Paris, France. This positive response to adalimumab was greatest for patients who had been intolerant of their anti-TNF therapies, or had lost their initial responses, compared with those who had had no response to prior anti-TNF therapies at all.

After 12 weeks of treatment with adalimumab, AS patients were found to have a mean reduction in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) of -2.4 following previous etanercept and/or infliximab treatment, and a reduction of -2.9 in those who have not had prior anti-TNF therapy. RA patients had a mean reduction in DAS28 (Disease Activity Scale 28) of -1.9 following previous treatment with either etanercept or infliximab.

Lead researcher, Dr G R Burmester of Berlin University Hospital, commented: "An increasing number of patients with rheumatic diseases, such as AS, RA or PsA, are experiencing an inadequate response to, or are intolerant of, treatment with existing anti-TNFs including etanercept or infliximab. The results of our study show that adalimumab offers new hope for those who have tried, but not responded well, to other treatment options for their diseases."

Ankylosing spondylitis

61% of AS patients who had lost their initial responses to previous anti-TNFs reached ASAS20 (a measure of 20% improvement in 4 domains commonly affected in AS including: pain, inflammation, function, and patient's global assessment of disease activity) after twelve weeks of adalimumab therapy and 42% of patients reached ASAS40 (a 40% improvement across these domains)
'/>"/>

Contact: Rory Berrie / Camilla Dormer
eularpressoffice@uk.cohnwolfe.com
44-078-761-90439
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
2. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
3. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
4. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
5. Latest research on allergies: Specific immunotherapy can help
6. Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women
7. Breakthrough Isolaz(TM) Acne Therapy Featured in U.S. News & World Report:
8. Solid tumor cells not killed by radiation and chemotherapy become stronger
9. Specialist nurses can play a key role in supporting patients having radiotherapy
10. Majority of U.S. House Supports Repeal of Medicare Therapy Caps
11. Hill-Rom Innovative TotalCare(R) Bariatric Plus Therapy System Receives Gold Medical Device Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2008)...e based in the Northeast region with more hires,pl...HARRISBURG, Pa., Aug. 28 /PRNewswire-USNewswire/ -...red a Patient Safety Liaison for the,Northeast reg...he,Pennsylvania Patient Safety Reporting System (P...tizens., "Last year in focus groups with Pennsylv...
(Date:8/28/2008)... Leading dermatology company serves growing pro... Palo Alto, CA (PRWEB) August 28,... capital firm, today announced that together with ... is leading a Series A round of financing for Prof...ntly invested $15.5 million in the round. Profex, ...
(Date:8/28/2008)...jury, not injury itself, associated with increased... News) -- A group of researchers has described hou...ght to play a key role in Alzheimer,s disease. ,...beta, was directly linked to brain cell communicat...brain cell communication increased, so did amyloid...
(Date:8/28/2008)... The Accreditation Council for Continuing Medic...ision of the College of American Pathologists (CAP... a provider of continuing medical education for ph...L (PRWEB) August 28, 2008 -- The Accreditation Cou...awarded the Education Division of the www.cap.org...
Breaking Medicine News(10 mins):Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2Health News:College of American Pathologists' Education Division Receives Top Honor 2Health News:College of American Pathologists' Education Division Receives Top Honor 3
...ty Medical Center reveal a surprising new origin f...apparatus -- a stack of pancake-shaped compartmen...ular destinations -- is the source of a particular... Scientists have long thought that microtubules, ...
...ancer treatment comes in the form of Intraoperativ... of radiation during surgery . Thus the patient ca...the Princess Margaret Hospital team combined the e...cine specialists (radiation oncologists, physicist...
... Wednesday toward offering vaccinations against ce... that could be carried out by late next year. The...JCVI) recommended the use of vaccines to guard aga... transmitted infection which causes most cases of ...
...ersity School of Medicine in St. Louis have just g...ealing that smoking interferes with ligament heal...model and found that cigarette smoking impairs the...ite and delays healing following ligament repair s...
Other Medicine News:Health News:Research in the Origin of Microtubules 2Health News:Research in the Origin of Microtubules 3Health News:Intraoperative Radiation Therapy a New Step in Breast Cancer Treatment 2Health News:Girls Could Be Vaccinated Against Cervical Cancer in Britain 2Health News:Smoking Hampers Healing of the Ligament 2
(Date:8/27/2008)...es Crucial Breakthrough in Battle to Prevent ...CAGO, Aug. 27 /- The British Midlands...ntists at The University of Nottingham,have made a...vent the onset,of a very common type of dementia a...etically produced the first ever mouse model,with ...
(Date:8/27/2008)... BLISS-52 trial, expected by mid-2009 - - Data fr...l 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewswire-Fir...GSI ) today announced it has completed enrollment,...pivotal Phase 3,randomized clinical trials of Lymp...stemic lupus erythematosus (SLE). Belimumab is bei...
(Date:8/26/2008)...wswire/ -- Semafore Pharmaceuticals Inc.,announced...ess on Targeted,Therapies in Cancer in Washington,...of vascular-targeted PI3 kinase (PI3K) inhibitor S...PI3K is part of a very powerful pathway, the PI3/A...or role in cancer. Studies have shown that by,inhi...
(Date:8/26/2008).../- Healthpoint today announced,that i...ffectiveness of a,widely prescribed enzymatic debr...ing scars. The pilot study was prompted, in part, ...pertrophic scars and beneficial healing,properties...,2), "Given the findings from the peer-reviewed l...
Breaking Medicine Technology:The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Retina Group of New York To Present Seminar on Age Related Macular Degeneration 3B The Leading Cause of Visual Loss in Seniors 24388 1Retina Group of New York To Present Seminar on Age Related Macular Degeneration 3B The Leading Cause of Visual Loss in Seniors 24388 2Retina Group of New York To Present Seminar on Age Related Macular Degeneration 3B The Leading Cause of Visual Loss in Seniors 24388 3Mt Sinai 26apos 3Bs Children 26apos 3Bs Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 24385 1Mt Sinai 26apos 3Bs Children 26apos 3Bs Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 24385 2Rising energy food prices major threats to wetlands as farmers eye new areas for crops 4201 1Rising energy food prices major threats to wetlands as farmers eye new areas for crops 4201 2Rising energy food prices major threats to wetlands as farmers eye new areas for crops 4201 3Plant steroids offer new paradigm for how hormones work 4199 1Plant steroids offer new paradigm for how hormones work 4199 2Plant steroids offer new paradigm for how hormones work 4199 3
...(BUSINESS WIRE)--May 22, 2007 - Medtronic,(NYSE:MD...EAVOR,clinical trial program reinforcing the exist... drug-eluting coronary stent system.,Four-year res...trial and three-year results from the nearly 1,200...or is associated with sustained,safety, significan...
...ow Bifeprunox Maintained Stability,Significantly L...Lipid Profile Comparable with Placebo , MARIETTA, ...harmaceuticals, Inc., Wyeth Pharmaceuticals, a div...ted clinical study results on,bifeprunox, an inves...with schizophrenia, today at the 2007 annual meeti...
Other Medicine Technology:Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 2Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: